How we treat cytomegalovirus in hematopoietic cell transplant recipients-Reference-Cited by-同舟云学术

How we treat cytomegalovirus in hematopoietic cell transplant recipients

Published:2009-06-04 Issue:23 Volume:113 Page:5711-5719
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Boeckh Michael¹,Ljungman Per²

Affiliation:

1. Vaccine and Infectious Disease Institute and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA; and

2. Department of Hematology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

Abstract

AbstractCytomegalovirus (CMV) continues to cause major complications after hematopoietic cell transplantation (HCT). Over the past decade, most centers have adopted preemptive antiviral treatment or prophylaxis strategies to prevent CMV disease. Both strategies are effective but also have shortcomings with presently available drugs. Here, we review aspects of CMV treatment and prevention in HCT recipients, including currently used drugs and diagnostics, ways to optimize preemptive therapy strategies with quantitative polymerase chain reaction assays, the use of prophylaxis, management of CMV disease caused by wild-type or drug-resistant strains, and future strategies.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/113/23/5711/1313248/zh802309005711.pdf

Reference109 articles.

1. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.;Boeckh;Blood,2003

2. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease.;Krause;Bone Marrow Transplant,1997

3. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma.;Zaia;J Infect Dis,1997

4. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.;Broers;Blood,2000

5. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis.;Craddock;Br J Haematol,2001

Cited by 467 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preferred Therapy for Specific Viral Pathogens;2024 Nelson’s Pediatric Antimicrobial Therapy;2024-02-14

2. Cytomegalovirus Pneumonia in a Patient with Down Syndrome;Medicina;2024-01-30

3. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP);Bone Marrow Transplantation;2024-01-25

4. Viral monitoring in immunocompromised hosts;Molecular Medical Microbiology;2024

5. SOHO State of the Art Updates and Next Questions | CTLs for Infections Following Stem Cell Transplantation;Clinical Lymphoma Myeloma and Leukemia;2024-01